pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company
WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained release, drug delivery products for treating eye diseases, today announced that it has signed two funded technology evaluation agreements with a leading global pharmaceutical company. The agreements will each evaluate the use of pSivida's Durasert™ technology to deliver a specific compound to treat a significant ophthalmic disease.
"We are very pleased to be working with this leading global pharmaceutical company," said Dr. Paul Ashton, president and CEO of pSivida. "Our strategy includes partnering product development with market leaders in appropriate circumstances, allowing us to expand our reach beyond our own product development. This opportunity fits that criteria, and we are excited about the potential products."
Pas impossible qu'il s'agisse de Valeant pour Vesneo.
Une fusion Nicox/pPsivida serait pas idiote maintenant que Psivida est sur les rails. Le timing semble bon pour les 2 sociétés qui me paraissent pouvoir être complémentaires et ça permettrait à Nicox de migrer au nasdaq (même si psivida semble aussi délaissée par les investisseurs américains que Nicox l'est en France. Ca leur fait encore un point commun....).
.
Cela donnerait une raison de + à Valeant pour absorber plus tard les 2 d'un coup.